# Axsome Therapeutics (AXSM) — News

AXSM · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/axsm/news

## Recent headlines

- [AXSOME Therapeutics, Inc.: Deutsche Bank cuts target price to $267 from $280](https://www.ainvest.com/news/axsome-therapeutics-deutsche-bank-cuts-target-price-267-280-2609) — AInvest Wire, Sep 29, 2026
  Deutsche Bank has revised its price target for Axsome Therapeutics, Inc. (AXSM.O), cutting it to $267 from $280. This adjustment reflects the firm's updated assessment of the company's financial outlook and market dynamics. Axsome Therapeutics, a biopharmaceutical company focused on developing…
- [AXSOME Therapeutics, Inc.: Truist Securities assumes coverage with buy rating; target price $285 vs $200](https://www.ainvest.com/news/axsome-therapeutics-truist-securities-assumes-coverage-buy-rating-target-price-285-200-2609) — AInvest Wire, Sep 23, 2026
- [Axsome Therapeutics, - Doses first patient in summit phase 3 trial of AxS-05 for smoking cessation](https://www.ainvest.com/news/axsome-therapeutics-doses-patient-summit-phase-3-trial-axs-05-smoking-cessation-2608) — AInvest Wire, Aug 31, 2026
  Axsome Therapeutics has initiated a pivotal phase 2/3 clinical trial of AXS-05 for smoking cessation, marking a key milestone in the company’s development pipeline. The trial, which will evaluate the efficacy and safety of AXS-05 in helping patients quit smoking, is expected to expand the…
- [Axsome Therapeutics shares down 1.1% after Q2 revenue miss](https://www.ainvest.com/news/axsome-therapeutics-shares-1-1-q2-revenue-2608) — AInvest Wire, Aug 10, 2026
  Axsome Therapeutics (AXSM) reported second-quarter revenue of $18.5 million, falling short of the $21.3 million consensus estimate, according to data from Refinitiv [1]. The company's shares declined 1.1% in after-hours trading following the earnings release. The revenue shortfall was attributed to…
- [Axsome Therapeutics shares reverse course premarket; last up 2.2%](https://www.ainvest.com/news/axsome-therapeutics-shares-reverse-premarket-2-2-2608) — AInvest Wire, Aug 10, 2026
  Axsome Therapeutics, Inc. (NASDAQ:AXSM) shares reversed course in premarket trading on August 10, 2026, after rising 2.2% in the previous session. The stock closed at $212.74 on August 7, 2026, marking a 16.48% increase for the year . Over the past 52 weeks, AXSM shares have surged 139.54%,…

## Similar Stocks

- [JAZZ](https://www.lighthorse.io/tickers/jazz) — Jazz Pharmaceuticals plc - Ordinary Shares

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).